David Borges Sells 906 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 906 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $19.10, for a total transaction of $17,304.60. Following the completion of the transaction, the chief accounting officer directly owned 5,906 shares in the company, valued at approximately $112,804.60. The trade was a 13.30% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Down 0.2%

Omeros stock traded down $0.04 during mid-day trading on Tuesday, reaching $19.28. 1,314,611 shares of the company’s stock were exchanged, compared to its average volume of 1,716,966. The business’s fifty day simple moving average is $11.93 and its 200 day simple moving average is $11.81. The firm has a market capitalization of $1.40 billion, a PE ratio of 15.06 and a beta of 2.54. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. On average, sell-side analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Omeros has an average rating of “Moderate Buy” and an average target price of $38.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Omeros during the 2nd quarter valued at approximately $57,484,000. Vanguard Group Inc. lifted its stake in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares during the last quarter. UBS Group AG raised its position in Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after purchasing an additional 1,513,893 shares during the period. Geode Capital Management LLC boosted its stake in shares of Omeros by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock valued at $28,026,000 after purchasing an additional 95,979 shares during the period. Finally, State Street Corp increased its holdings in Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.